After receiving apabetalone, alterations in the proteome led to a predicted inhibition of TGF-β1 in CKD subjects by 12 h and maintained at 24 h post-dose; however, no prediction was made in control subjects. The gene discussed is TGFB1; the disease is chronic kidney disease.